Venture vs. The Virus: The Life Science/Healthcare Outlook for Fundraising During a Pandemic
May 13 @ 12:00 PM – 1:00 PM
I know what you’re thinking…it’s hard enough to raise venture capital for life science/healthcare startups in normal times, but throw a global pandemic and economic meltdown into the mix and even the best-laid plans will certainly go astray! So here are the questions that entrepreneurs would like answers to: Is there an inevitable slowdown in venture financing? How can VC firms conduct due diligence efficiently and thoroughly during a lockdown? Is a videoconference enough to establish a trusting relationship with a CEO and a Board? Does every startup have to take a hit on valuation if they want to get funding? Has the Coronavirus fundamentally changed expectations, time horizons, governance, and risk tolerance? What’s it gonna take to get someone to write a check?
Join us for a lively and informative session featuring Venture Capital professionals adept at telling their stories, listening to entrepreneurs gripe about funding, and answering the most perplexing questions as if they were Carnac the Magnificent!
Meet Our Moderators and Panelists:
Jeffrey Hausfeld, M.D., M.B.A – Chairman of the Board and Chief Medical Officer at BioFactura, Inc., Chairman and Co-Founder SoPE
Jeffrey Hausfeld, M.D., M.B.A., F.A.C.S., has served on the national board and committees of specialty medical societies since he began his practice in Otolaryngology/Facial Plastic Surgery in 1982. He is an Associate Clinical Professor of Surgery at George Washington University School of Health Sciences and an alumnus of the Yale University School of Medicine. Dr. Hausfeld is widely published in the medical literature, is the pioneer of innovative laser surgery techniques, is the author of a lay oriented medical book on snoring and sleep apnea, and has appeared on numerous local and national television and radio shows as a medical expert. He has also served as a health care consultant, spokesperson, and executive coach for multi-national pharmaceutical companies, health care firms, as well as the U.S. military. Dr. Hausfeld stepped down from his clinical duties after receiving a Masters in Business Administration from Johns Hopkins University. Dr. Hausfeld is presently developing assisted living facilities specializing in Alzheimer’s and dementia care. He serves as a consultant to several healthcare/life science startups in diagnostics, devices, biotech and Health IT. He also serves on the Investment Advisory Board of the Center for Innovation Technology’s Life Science Gap Fund. The fund supports promising healthcare and life sciences ventures in the Commonwealth of Virginia. Dr. Hausfeld is the Chairman and Founder of the Society of Physician Entrepreneurs (www.sopenet.org ), a global network focused on educating healthcare and life science professionals in Bioentrepreneurship and Innovation. Dr. Hausfeld is orchestrating the Series C Financing of BioFactura (www.biofactura.com) and acted as the lead investor in previous rounds. He serves as Chairman of the Board of BioFactura as well as their Chief Medical Officer as the company develops its Biosimilar platform as well as its novel Bio-defense therapeutics.
Rania Nasis, MD, MBA
Director, Society of Physician Entrepreneurs (SoPE) and New York Tristate Chapter Co-Leader
Rania is a physician entrepreneur and seasoned operator with a passion for building companies to address unmet needs in healthcare. She is the founder of Starlings, an advisory firm that works with early stage healthcare startups on strategy, operations and product-market fit. She is also a Director of the Society of Physician Entrepreneurs (SoPE), a non-profit global biomedical and healthcare innovation network. She has a wide breath and depth of experience across a multitude of areas in healthcare, including digital health, aging tech, biotech, life sciences, devices, and diagnostics. She has previously held senior leadership roles within multiple healthcare startups.
She received her MD from New Jersey Medical School, MBA from the Paul Merage School of Business at University of California at Irvine and BS from Drexel University.
Adair Newhall, Principal – Greenspring Associates
Adair is responsible for sourcing and due diligence efforts on fund, direct and secondary opportunities. He leads the firm’s healthcare and portfolio impact practices. Adair currently serves on the Bright Health & Crown Labs boards and sits as an observer on the Paladina Health board. He also advises five different Venture Advisory Boards for venture capital firms and five passive direct healthcare investments (Imago Biosciences, Kallyope, NGM Bio, Phathom Pharma, PowerVision, & ScoutBio). He received his MBA from the Darden Graduate School of Business Administration at the University of Virginia and his undergraduate degree from the University of Pennsylvania. Adair is a Kauffman Fellow, a member of the Baltimore/Washington Chapter of YPO, and a co-founder of the UVa Venture Summit.
Andrea Alms, Co-Fund Manager – BioHealth Capital Fund
The BioHealth Capital Fund is a venture capital early stage investment fund created by the BioHealth Innovation (“BHI”), located in Rockville, MD, the center of the BioHealth Capital Region. BHI manages a for profit subsidiary BioHealth Innovation Management (BHIM) which owns equity in 27 of the 108 client companies of BHI and has had 3 exits. Our lead investor is Alexandria Real Estate Equities. Andrea is recognized for her abilities in guiding venture capital, private equity, mergers and acquisitions (M&A), and other transactions involving biohealth companies. Andrea assists limited partners, general partners, investors with lauching and operating secondary and primary investment funds. Wellesley College (BA), Averett University (MBA), and U.Va. (M.S., Pharmacology).
Matthew Miessau, Associate – Epidarex Capital
Bethesda-based venture capital firm Epidarex Capital finds, invests in, and builds early-stage breakthrough life sciences companies in emerging hubs. Mr. Miessau is also currently an instructor at the NIH Foundation for Advanced Education in the Sciences (FAES), teaching Biomedical Business Development for Scientists. Prior to joining Epidarex, he was the Program Manager for the Georgetown University Center for Drug Discovery. Mr. Miessau holds an M.S. in biotechnology and a B.S. in biochemistry from Georgetown University.
Adam Dakin, Managing Director – Dreamit Healthtech
Adam serves as the Managing Director for Dreamit Ventures where he leads the HealthTech vertical. Dreamit focuses on seed and Series A digital health and medtech companies. His career has focused on building early stage venture-backed healthtech companies. He co-founded five health technology companies which have collectively raised over $60M in early stage capital. Adam serves on the boards of Safkan Health and ZSX Medical, and is an active angel investor. He is a named inventor on seven U.S. patents. Adam holds a BSE from the Wharton School and an MBA from UCLA.